EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.22

Change

+0.34 (+3.44)%

Market Cap

N/A

Volume

1.08M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+1.64 (+0.99%)

USD 76.41B
HLN Haleon plc

N/A

USD 42.79B
TAK Takeda Pharmaceutical Co Ltd A..

+0.18 (+1.39%)

USD 41.33B
RDY Dr. Reddy’s Laboratories Ltd..

-0.10 (-0.67%)

USD 12.60B
ELAN Elanco Animal Health

+0.02 (+0.17%)

USD 5.65B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.30 (+3.63%)

USD 3.68B
BHC Bausch Health Companies Inc

+0.03 (+0.40%)

USD 2.91B
CPHI China Pharma Holdings Inc

+0.01 (+2.86%)

USD 3.69M
YCBD cbdMD Inc

+0.01 (+2.79%)

USD 1.96M
EVT Eaton Vance Tax Advantaged Div..

+0.19 (+0.78%)

N/A

ETFs Containing EBS

XB4A:F Xtrackers ATX UCITS ETF 1.. 19.72 % 0.00 %

+0.10 (+1.83%)

USD 0.04B
XB4A:XETRA Xtrackers ATX UCITS ETF 1.. 19.25 % 0.00 %

-0.20 (1.83%)

USD 0.05B
EXXX:XETRA iShares ATX UCITS ETF (DE.. 18.99 % 0.00 %

-0.07 (1.83%)

USD 0.09B
BNKE:LSE Lyxor EURO STOXX Banks UC.. 3.04 % 0.00 %

-0.24 (1.83%)

USD 0.30M
C005:XETRA Amundi Index Solutions - .. 2.32 % 0.00 %

-0.14 (1.83%)

USD 0.13B
IS3H:XETRA iShares MSCI EMU Mid Cap .. 2.22 % 0.00 %

+0.12 (+1.83%)

USD 0.13B
BINV 2023 ETF Series Trust - B.. 2.15 % 0.00 %

+0.55 (+1.83%)

USD 0.14B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.93 % 0.00 %

-0.03 (1.83%)

USD 0.14B
FTGE:XETRA First Trust Eurozone Alph.. 1.34 % 0.00 %

-0.29 (1.83%)

USD 0.08B
FEUZ:LSE First Trust Eurozone Alph.. 1.32 % 0.00 %

-8.00 (1.83%)

USD 0.06B
FEUD:LSE First Trust Eurozone Alph.. 1.32 % 0.00 %

-8.25 (1.83%)

USD 0.01B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+0.90 (+1.83%)

N/A
LDEU:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+0.02 (+1.83%)

USD 0.04B
EL43:XETRA Deka MSCI Europe MC UCITS.. 1.18 % 0.00 %

+0.05 (+1.83%)

USD 0.02B
EUMD:LSE iShares MSCI Europe Mid C.. 1.18 % 0.00 %

+0.01 (+1.83%)

USD 0.28B
FEP First Trust Europe AlphaD.. 1.02 % 0.80 %

+0.81 (+1.83%)

USD 0.19B
FDT First Trust Developed Mar.. 0.66 % 0.80 %

+0.95 (+1.83%)

USD 0.39B
PRFZ Invesco FTSE RAFI US 1500.. 0.35 % 0.39 %

+0.58 (+1.83%)

USD 2.60B
IS3T:XETRA iShares MSCI World Size F.. 0.15 % 0.00 %

+0.13 (+1.83%)

USD 0.24B
FEUZ First Trust Eurozone Alph.. 0.00 % 0.80 %

+0.77 (+1.83%)

USD 0.02B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.26 (+1.83%)

N/A
FTEU:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

-0.05 (1.83%)

USD 0.06B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.90% 86% B+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.90% 86% B+ 84% B
Trailing 12 Months  
Capital Gain 418.78% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 418.78% 100% F 100% F
Trailing 5 Years  
Capital Gain -82.41% 23% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.41% 23% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -16.79% 7% C- 3% F
Dividend Return -16.79% 7% C- 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 105.60% 21% F 8% B-
Risk Adjusted Return -15.90% 21% F 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector